Crossmark

t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab

Crossref DOI link: https://doi.org/10.1007/s00277-025-06282-5

Published Online: 2025-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Geyer, Julia T.

Ruan, Jia

Kluk, Michael J.

Bao, Liming
License Information

Text and Data Mining valid from 2025-02-27

Version of Record valid from 2025-02-27
More Information

Article History

Received: 29 April 2024

Accepted: 20 February 2025

First Online: 27 February 2025

Declarations

:

: The study was conducted following the Declaration of Helsinki and approved by Institutional Review Boards. Written consent was obtained from the patient.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below